OncoZenge Q2 FY26 operating loss widens to SEK 5.4 million; net sales rise to SEK 5.8 million

• OncoZenge posted Q2 net sales of SEK 5.8 million, versus no net sales a year earlier.
• Operating loss widened to SEK 5.4 million, while loss after tax deepened to SEK 5.7 million; EPS was SEK -0.40.
• Cash flow was SEK -0.2 million, with cash and cash equivalents at SEK 0.7 million as of June 30.
• Board approved a rights issue of up to SEK 33.3 million to fund the Phase III BEAM-Pain trial for BupiZenge.
• Trial enrolled its first patient on July 7; the offer is about 80% covered by SEK 5.5 million subscriptions and SEK 21.2 million guarantees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncozenge AB published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.